Key Takeaways:
A federal court order forcing the Centers for Medicare & Medicaid Services to upgrade Clover Health's Medicare Star Rating from 3.5 to 4.5 Stars has added more than $400 million to the insurer's market value in two days.
Clover Health Investments Corp. shares surged 18.9% on Wednesday and extended gains Thursday, trading 4.9% higher at $5.13 as of 11:32 a.m. in New York. The rally added roughly $430 million to the company's market capitalization following a court ruling that directly boosts its government reimbursement rates.
"The Star Rating upgrade is a material financial event for Clover because it directly increases the benchmark payments we receive from CMS for Payment Year 2027," said Andrew Toy, chief executive officer of Clover Health, in a statement accompanying the company's SEC filing. "This ruling validates our commitment to delivering high-quality care to our members."
The U.S. District Court for the Southern District of Georgia entered final judgment on May 29 in Clover Insurance Co. v. U.S. Department of Health and Human Services, granting partial summary judgment to Clover's subsidiary. The court set aside the company's 2026 3.5 Star Rating for Contract H5141 and ordered CMS to recalculate. On June 9, CMS informed Clover it had recalculated the rating to 4.5 Stars and directed the company to submit alternate bids at the higher level.
The upgraded rating applies to Clover's PPO plan, which covers more than 97% of the company's members. The company's HMO plan was not part of the litigation and retains its 4.0 Star Rating. Medicare Star Ratings determine quality bonus payments, with each half-star increment translating into meaningful revenue differences under CMS's benchmark payment formula.
The jump from 3.5 to 4.5 Stars represents a two-notch improvement that significantly increases Clover's revenue per member from CMS for Payment Year 2027. Medicare Advantage plans with 4 Stars or higher receive quality bonus payments that can add 5% or more to benchmark rates, according to CMS methodology.
Clover Health has been targeting its first-ever full year of net income profitability in 2026, and the higher reimbursement rates from the upgraded rating strengthen the path to that goal. The company's medical loss ratio — the share of premium dollars spent on medical claims — will be a key metric for investors assessing whether the additional revenue flows to the bottom line.
The ruling could have broader implications for the Medicare Advantage industry. Other insurers that have disputed their Star Ratings may pursue similar legal challenges, potentially forcing CMS to defend its rating methodology in court more frequently. The Medicare Advantage program covers more than 33 million beneficiaries, with total federal spending exceeding $475 billion annually.
Clover Health's stock has more than doubled from its 52-week low of $2.41, though it remains well below its all-time high of $28.85 reached in early 2021 during the SPAC boom. The company went public via a merger with Social Capital Hedosophia in January 2021.
This article is for informational purposes only and does not constitute investment advice.
